Biote Corp

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company is headquartered in Irving, TX.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biote Corp reports robust Q2 earnings, eyes men's health market

Biote Corp's Q2 2023 earnings call highlighted strong financial and strategic progress, marked by revenue growth, improved operating income, and a focus on expanding into new markets. While facing realignment challenges, the company remains confident in its outlook for continued growth and is dedicated to offering innovative wellness solutions.

Biote Corp reports revenue growth and plans nationwide wellness launch

Biote Corp (BTMD) demonstrated positive financial performance in Q3 2023 with revenue growth and improved EBITDA margin, driven by dietary supplements and procedures.
The company's strategic focus on expanding product offerings, engaging with key opinion leaders, and realigning sales territories positions them for future growth.
While facing challenges in procedure revenue growth and market dynamics, Biote Corp's initiatives to launch new offerings and target men's health present opportunities for expansion.

Biote Corp reports robust 2023 growth and targets strategic expansion

Biote Corp (BTMD) delivered strong financial performance in 2023 and sets ambitious targets for 2024, focusing on growth and efficiency.
The company's strategic initiatives, including new offerings and acquisitions, position it well for expansion and market leadership.
Challenges lie in optimizing operations and integration efforts, but Biote's commitment to innovation and growth bodes well for the future.

Biote Corp reports revenue growth and strategic acquisitions in Q1

Biote Corp (BTMD) delivered a solid performance in Q1 2024, marked by revenue growth, improved EBITDA, and strategic acquisitions.
While challenges like declining dietary supplement revenue and analyst inquiries exist, the company's strengths in product innovation and financial outlook bode well for future growth.
By capitalizing on opportunities in product development, geographic expansion, and market demand for wellness solutions, Biote Corp can further solidify its position in the industry.

Biote Corp reports solid Q3 earnings, eyes growth opportunities

Biote Corp (BTMD) delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency.
While facing temporary challenges, the company remains focused on growth opportunities through market expansion and operational enhancements.
With a strategic focus on top-tier accounts, practitioner training, and technology integration, Biote is poised for continued success and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. It delivers a comprehensive, end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support. The company was founded in 2012 and is headquartered in Irving, TX.

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten offering of 5,217,392 shares of its Class A common stock by one its stockholders at a price of $5.35 per share. The selling stockholder has granted the underwriter a 30-day option to purchase an aggregate of not more than 782,608 additional shares of the Company's C.

Biote Announces Pricing of Secondary Offering of Common Stock

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced its participation at the following investor conferences: On June 6, 2023, Terry Weber, Biote's Chief Executive Officer, and Samar Kamdar, Biote's Chief Financial Officer, will present at 10:40 AM ET at TD Cowen's 7th Annual Future of the Consumer Conference in New York, NY. Marc Beer, B.

Biote to Participate at Upcoming Investor Conferences

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote's commercial initiatives to expand the Company's presence in the growing market for hormone replacement therapy. Ms. Puncochar joins Biote with more than 30 years of experience.

Biote Appoints Mary J. Puncochar as Chief Commercial Officer

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD) (the “Company,” “we” or “us”), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its (i) 8,397,624 outstanding public warrants (the “Public Warrants”) to purchase Class A common stock of the Company $0.0001 par value per share (“Class A Common Stock”).

Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Highlights, year-over-year: Revenue of $44.8 million, a 20.7% increase Gross profit margin of 69.1%, a 220-basis point increase Net loss of $(21.4) million and GAAP loss per share of $(0.39), primarily reflecting the impact of tr.

Biote Reports First Quarter 2023 Financial Results

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide first quarter financial results on Tuesday, May 9, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, May 10, 2023, at 8:30 a.m. ET. Conference Call Details The conference call may be accessed by dialing (844) 481-.

Biote Schedules First Quarter 2023 Financial Results Release and Conference Call

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne has joined the Company as General Manager, Men's Health Division. In this role, Denne will lead Biote's sales initiatives to expand the Company's presence in the growing market for male hormone replacement therapy.

Biote Names John Denne as General Manager, Men's Health Division

The mean of analysts' price targets for biote Corp. (BTMD) points to an 82.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does biote Corp. (BTMD) Have the Potential to Rally 82.51% as Wall Street Analysts Expect?

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter Highlights, year over year: Revenue of $44.5 million, an 18.5% increase. Net income of $12.8 million and fully diluted GAAP earnings per share of $0.18. Adjusted EBITDA of $13.1 million, a 40% increase.

Biote Reports Fourth Quarter and Full Year 2022 Financial Results

IRVING, Texas--(BUSINESS WIRE)---- $BTMD #antiaging--In a case study, a 54-year-old male patient with a spontaneous fracture and osteoporosis achieved an “almost complete recovery of osteoporosis” after one year of pelleted testosterone therapy and experienced improvements in quality of life and sleep apnea.

Study: Testosterone Pellet Therapy Significantly Improves Bone Density in Male Patient Case Report

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the 35th Annual Roth Conference, to be held March 12-14, 2023, in Dana Point, CA. Biote's Chief Executive Officer, Terry Weber, and Chief Financial Officer, Samar Kamdar, will present at the conference on March 14, 2023, at 10:00 a.m. local time. Ms. Weber, Mr.

Biote to Present at 35th Annual Roth Conference

IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on Tuesday, March 28, 2023, after the close of the market. A conference call to discuss the firm's results will be held Wednesday, March 29, 2023 at 8:30 a.m. ET.

Biote Schedules Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call

IRVING, Texas--( BUSINESS WIRE )--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the closing of its previously announced underwritten public offering of 8,500,000 shares of its Class A common stock by certain of its stockholders, including the full exercise of the underwriters' option to purchase 1,108,695 shares of Class A common stock, at a price to the public of $3.00 per share. Biote is not receiving any proceeds from the offering.

Biote Announces Closing of Secondary Offering of 8,500,000 Shares of Common Stock Including Full Exercise of the Underwriters' Over-Allotment Option

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the Jefferies London Healthcare Conference, November 15-17, 2022, in Aldwych, London.

Biote to Present at Jefferies London Healthcare Conference

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced financial results for the third quarter ended September 30, 2022.

Biote Reports Third Quarter Financial Results

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote's Board of Directors.

Biote Appoints Debby Morris to Board of Directors

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide third quarter financial results on Tuesday, November 8, 2022, after the close of the market.

Biote Schedules Third Quarter 2022 Financial Results Release and Conference Call

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time in communications with investors or potential investors. The updated presentation for October can be found under the Investor Relations section of biote's website at https://ir.biote.com/news-events/presentations. About

Biote Releases Updated Corporate Presentation for October 2022

Imac Holdings Inc

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has entered into a partnership with IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”) a regenerative rehabilitation company focused on treating musculoskeletal and neurodegenerative disease. Through this partnership, IMAC will add certain Biote services to its network of outpatient clinics

Biote Announces Strategic Partnership with IMAC Holdings, Inc.

IRVING, Texas--(BUSINESS WIRE)--Biote Announces Approval to Relist on The Nasdaq Stock Market

Biote Announces Approval to Relist on The Nasdaq Stock Market

IRVING, Texas--(BUSINESS WIRE)--Biote Appoints Samar Kamdar as Chief Financial Officer

Biote Appoints Samar Kamdar as Chief Financial Officer

IRVING, Texas--(BUSINESS WIRE)--Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled “Biote Reports Second Quarter 2022 Financial Results,” issued on August 9, 2022. The other financial results reported in the original press release, revenue and adjusted EBITDA, as well as Biote's full year guidance with respect thereto, were not impacted by the corrections. The corrections are as follows (in thousan

Biote Issues Correction to Second Quarter Operating Loss and Net Income

IRVING, Texas--(BUSINESS WIRE)--Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financial results for the second quarter ended June 30, 2022. Terry Weber, Chief Executive Officer, and the Company's management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, August 10, 2022. To access the conference call by telephone, please dial 877-545-0523 (do

Biote Reports Second Quarter 2022 Financial Results

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022, after market close on Tuesday, August 9, 2022. Terry Weber, Chief Executive Officer, and the Company's management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, August 10

Biote to Report Second Quarter 2022 Financial Results on August 9, 2022 and Host Conference Call on August 10, 2022

IRVING, Texas--(BUSINESS WIRE)--Biote Appoints Ross W. McQuivey, M.D. as Chief Medical Officer

News for Biote Corp Stock (BTMD)